Notice NOT-DE-18-001 from the NIH Guide for Grants and Contracts

Notice NOT-EY-18-002 from the NIH Guide for Grants and Contracts

Notice NOT-EY-18-001 from the NIH Guide for Grants and Contracts

Notice NOT-GM-18-003 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-010 from the NIH Guide for Grants and Contracts

Notice NOT-GM-18-004 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-407 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement a Clinical Coordinating Center for investigator-initiated multi-site clinical trials (Phase II and beyond). Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website: http://www.nhlbi.nih.gov. This FOA will utilize a bi-phasic, milestone-driven cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Data Coordinating Center (PAR-16-301). The objective of the Clinical Coordinating Center application is to present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes it. The application should include plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. Both a Clinical Coordinating Center (CCC) application and a collaborating Data Coordinating Center (DCC) application must be submitted on the same application due date for consideration by NHLBI. Applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application.

Funding Opportunity PAR-18-410 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications for a collaborating Data Coordinating Center (DCC) for investigator-initiated multi-site clinical trials (Phase II and beyond). Trials for which this FOA applies must be relevant to the research mission of the NHLBI and meet the definition of an NIH clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website. This FOA will utilize a cooperative agreement mechanism of award and runs in parallel with a companion FOA that encourages applications for a collaborating Clinical Coordinating Center (PAR-FY-NNN). The DCC application must be specific for the clinical trial being proposed in the collaborating Clinical Coordinating Center (CCC). The objective of the DCC application is to present a comprehensive plan to provide overall project coordination, administration, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a collaborating CCC application must be submitted on the same application due date for consideration by NHLBI. Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

Funding Opportunity RFA-ES-18-001 from the NIH Guide for Grants and Contracts. The Outstanding New Environmental Scientist (ONES) Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on the understanding of environmental exposure effects on peoples health.

Funding Opportunity RFA-AI-17-037 from the NIH Guide for Grants and Contracts. The goal of this reissued Funding Opportunity Announcement (FOA) is to expand understanding of age-related changes that occur in immune function during the aging process that influence responses to pathogens and/or vaccines, as well as oral and craniofacial health. Human studies are required, and inclusion of relevant animal studies is permitted for mechanistic understanding. This FOA solicits applications that will determine the mechanisms required for induction and maintenance of protective immunity in the elderly in response to infections and/or vaccinations, including the effects of chronic inflammation on those responses, and applications that will assess changes in immune processes in dental, oral and craniofacial tissues in the elderly.

Funding Opportunity RFA-AG-18-020 from the NIH Guide for Grants and Contracts. The National Institute on Aging (NIA) solicits research projects that would advance our understanding of how protein homeostasis (proteostasis) in peripheral tissues affects brain aging, leading to the development of Alzheimers Disease (AD). Much research on AD has focused on the accumulation of aberrant protein aggregates in the brain, and in particular amyloid and Tau. Formation of aggregates due to mutations encoded in the APP gene or due to hyperphosphorylation, respectively, have been linked to familial AD. The etiology of the more common, sporadic form of AD, is less certain, although aging is considered a major risk for development of the disease. It is known that proteostasis is less efficiently maintained in all tissues with aging, and this may indicate a link between proteostasis in the periphery and the appearance of aging-related diseases and conditions, including the decline in cognitive function, as well as dementia and AD. Therefore, testing for a role of aging-related loss of peripheral proteostasis in the development of AD is the focus of this FOA.

Funding Opportunity PAR-18-329 from the NIH Guide for Grants and Contracts. This Small Business Innovation Research (SBIR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R and D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).

Funding Opportunity PAR-18-326 from the NIH Guide for Grants and Contracts. This Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R and D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).

Funding Opportunity PAR-18-333 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support studies on the very early development of the immune system and the humoral and cellular communication that exists between the mother and fetus that may shape or impact immune system development and maturation.

Funding Opportunity PAR-18-406 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports applications to develop and implement phase II and beyond investigator-initiated single-site clinical trials. Applications submitted to this FOA must be relevant to the research mission of the NHLBI and meet the NIH definition of a clinical trial (see NOT-OD-15-015). For additional information about the mission, strategic vision, and research priorities of the NHLBI, applicants are encouraged to consult the NHLBI website: http://www.nhlbi.nih.gov. This FOA will utilize a bi-phasic, milestone-driven mechanism of award. It is anticipated that applications will present the scientific rationale for the clinical trial and a comprehensive scientific and operational plan that describes the conduct of the trial, as well as plans for project management, subject recruitment and retention, performance milestones, scientific conduct of the trial, and dissemination of results. The multiple PD/PI model is strongly encouraged but not required. Applicants are encouraged to include a PD/PI with expertise in biostatistics, clinical trial design, and coordination. Due to the complex nature of conducting a clinical trial, applicants are strongly encouraged to contact the appropriate Scientific/Research contact prior to submitting an application. Staff will be able to assist applicants in meeting the objectives of this FOA.

Funding Opportunity RFA-AG-18-019 from the NIH Guide for Grants and Contracts. The overall goal of this funding announcement is to solicit applications to investigate the central neural control of mobility in older adults without overt neurological diseases using innovative and cutting-edge methods that are emerging in neuroscience, geriatrics and mobility-related fields in aging research communities. This announcement also seeks information on the degree of plasticity in the aging brain and how this may be harnessed to maintain or improve mobility. Applicants are highly encouraged to adapt a multidisciplinary and collaborative approach that includes basic, clinical, and translational scientists. Mobility impairments are common in aging and are associated with a host of adverse events including disability and mortality. Identifying novel modifiable predictors of mobility decline will lead to mechanistic insights and the development of novel therapeutic interventions to enhance mobility as a person ages.

Notice NOT-OD-18-009 from the NIH Guide for Grants and Contracts

Notice NOT-OD-18-007 from the NIH Guide for Grants and Contracts

Notice NOT-RM-18-001 from the NIH Guide for Grants and Contracts

Notice NOT-DA-17-055 from the NIH Guide for Grants and Contracts